IperionX Limited (ASX:IPX): Titanium Manufacturing Expansion and Defence Programs

Aditi Sarkar

05 November 2026 08:50 PM AEDT

IperionX Limited (ASX:IPX): Titanium Manufacturing Expansion and Defence Programs

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

September-quarter titanium powder production reached 8.7 tons, compared with 1.4 tons in June.
The company validated annualised HAMR furnace capacity above 200 tons.
GenX continuous processing demonstrated an equivalent production rate of approximately 100 tons annually.
Defence-related customer testing and titanium fastener Manufacturing progressed.
Funding and manufacturing expansion remain important to the company’s next development stage.

IperionX Limited (ASX:IPX) develops titanium metal production and manufacturing processes, with operations centred on its Virginia Titanium Manufacturing Campus in the United States. Its activities encompass titanium powder, fabricated components and mineral resources. During the September 2026 quarter, the company reported higher powder output, progress in Downstream manufacturing and further work on defence-related customer programs. These developments distinguish validated equipment capacity from actual production delivered during the reporting period.

Titanium Powder Output and Processing Capacity

IperionX (ASX:IPX) produced 8.7 tons of titanium powder during the quarter ended 30 September 2026, compared with 1.4 tons in the preceding June quarter. At period-end, the company held 19 tons of finished titanium powder and 207 tons of titanium scrap feedstock. The inventory provides material for manufacturing activities, although finished powder inventory is not equivalent to completed component deliveries.

The company reported that its hydrogen-assisted metallothermic reduction, or HAMR, furnace had demonstrated capacity above a 200-ton-per-year annualised rate. This is a measure of validated operating capability, not a statement that 200 tons were manufactured during the quarter. IperionX (ASX:IPX) also reported continued operation of its powder production systems on a continuous schedule.

Its GenX continuous platform processed more than 500 kilograms across four runs totalling 41 hours. The company validated an equivalent annualised production rate of approximately 100 tons. On a like-for-like runtime basis against batch HAMR, it reported sixfold throughput, alongside reductions of more than 75% in electricity use, 45% in magnesium use and 60% in hydrogen use per kilogram. These results describe company-reported process tests, rather than sustained commercial-scale economics.

Fasteners, Customer Qualification and Defence Work

Manufacturing development at IperionX (ASX:IPX) increasingly extends beyond powder production. The company reported cumulative production of 1,500 titanium fasteners and expanded in-house pressing, sintering, heat treatment, machining and thread-rolling capabilities. One additional sintering furnace was commissioned, while a second was installed and scheduled for commissioning in the December 2026 quarter.

Customer work includes titanium components for a United States Navy pump supplier, which entered final testing, and prototype track pins for a United States Army vehicle program. The company also secured a follow-on fastener purchase order from the Army’s Ground Vehicle Systems Center. Qualification and testing are necessary steps before potential larger-scale orders; prototypes and purchase orders should not be treated as evidence of recurring production revenue.

Funding, Expansion and Execution Risks

At 30 September 2026, IperionX (ASX:IPX) reported US$63.0 million in cash, compared with US$35.2 million at the end of June. Quarterly net operating cash outflow was US$12.6 million. The company identified remaining obligated government reimbursements of US$33.7 million, giving reported available Liquidity of approximately US$96.7 million when combined with cash. Reimbursement arrangements and cash balances represent different forms of funding.

The company is pursuing an expansion toward 1,400 tons of annual titanium production capacity, supported by government awards. The planned scale-up entails equipment installation, commissioning and manufacturing qualification. Commercial output could differ from demonstrated furnace rates because downstream capacity, product specifications and customer acceptance must also align. Operating cash requirements and project execution remain relevant considerations.

Key Insights

The September quarter showed progress in titanium powder output and the development of finished-product manufacturing. For IperionX (ASX:IPX), the distinction between tested production capacity, actual tonnage and qualified customer orders remains central to interpreting operational milestones. Its reported liquidity supports ongoing activity, while expansion spending and customer qualification will shape how manufacturing capabilities translate into routine deliveries.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.